Zenas BioPharma (NASDAQ:ZBIO) Shares Down 8% – Here’s What Happened

Posted by Geri Gentry on Jul 10th, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) was down 8% on Friday . The company traded as low as $26.95 and last traded at $27.0850. 95,055 shares changed hands during trading, a decline of 89% from the average daily volume of 855,310 shares. The stock had previously closed at $29.43.

Analysts Set New Price Targets

ZBIO has been the subject of several analyst reports. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Morgan Stanley increased their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Wednesday, June 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma currently has a consensus rating of “Moderate Buy” and an average price target of $44.29.

Read Our Latest Stock Analysis on Zenas BioPharma

Zenas BioPharma Trading Down 5.8%

The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The firm has a market cap of $1.75 billion, a P/E ratio of -3.29 and a beta of -0.96. The firm’s 50-day simple moving average is $20.68 and its 200 day simple moving average is $22.71.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. As a group, analysts expect that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the stock in a transaction on Monday, May 18th. The shares were acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the acquisition, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at $1,636,144.64. The trade was a 162.48% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have acquired 120,000 shares of company stock worth $2,080,000. Insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ZBIO. Geode Capital Management LLC grew its position in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares in the last quarter. Rhumbline Advisers raised its position in shares of Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares in the last quarter. Sei Investments Co. bought a new stake in Zenas BioPharma during the second quarter valued at $118,000. Bank of America Corp DE boosted its stake in Zenas BioPharma by 32.3% during the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after buying an additional 3,412 shares during the period. Finally, Vanguard Group Inc. grew its position in Zenas BioPharma by 17.2% during the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after buying an additional 170,546 shares in the last quarter.

Zenas BioPharma Company Profile

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.